| Description |
BCX-1898, a cyclopentane derivative, is an orally active and selective influenza virus neuraminidase inhibitor. BCX-1898 has antiviral activity with EC50s of <0.01-21 μM on influenza A (H1N1, H3N2, and H5N1) and influenza B viruses replication in MDCK cells. BCX-1898 shows protection against the mouse influenza model[1][2].
|
| Related Catalog |
|
| In Vivo |
BCX-1898 (1, 10 mg/kg/天; 口服给药; 22 天) 以 10 mg/kg/天显示出对流感病毒的完全保护[2]。 BCX-1898 (0.01, 0.1 mg/kg/天; 鼻内给药; 20 天) 表现出完全保护作用 (10 个模型中有 10 存活)[2]。 Animal Model: Mice (13-18 g) infected with the A/Turkey/Mas/ 76 X A/Beijing/32/92 (H6N2) influenza virus[2] Dosage: 1, 10 mg/kg/day Administration: Oral; 22 days Result: Showed complete protection against the influenza virus with 10 mg/kg/day, whereas at dose level (1 mg/kg/day) showed only a 10% protection against the influenza virus.
|
| References |
[1]. D F Smee, et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother. 2001 Mar;45(3):743-8. [2]. Pooran Chand, et al. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. Bioorg Med Chem. 2005 Jun 2;13(12):4071-7.
|
